Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs
Complete the form below to unlock access to ALL audio articles.
Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.
“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and Chief Executive Officer.
“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr. Ziping Wei, BlissBio’ Chief Executive Officer.